Latest in Tag: Ibnsina Pharma Highlight
Latest in Tag: Ibnsina Pharma
Partnership will give patients across Egypt unprecedented access to latest pharmaceutical treatments available: Ibnsina Pharma Chairperson
The step is considered the second of Ibnsina Pharma’s digital transformation plan, following the launch of its online ordering application last July.
Ibnsina Pharma achieved profits amounting to EGP 328.77m in the full year 2019 compared to EGP 262.5m in the previous full year.
The company posted gross profit of EGP 292.7m and gross profit margin of 7.85% in 1Q19, up approximately 0.4 percentage points from 7.49% in 1Q18.
Ibnsina Pharma, Egypt’s fastest-growing and the second-largest pharmaceutical distributor, succeeded in increasing its net revenues by 39% year-on-year (y-o-y) to reach EGP 13.3bn, in 2018, according to the company’s audited results which were announced on Sunday. Ibnsina’s gross profit for the period grew by 36% y-o-y to reach EGP 1.1bn in 2018, yielding a gross …
Ibnsina Pharma achieved net revenues of EGP 2.9bn, up 51.1% year-over-year in the first quarter of 2018, the company announced on Monday. The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) recorded a 69.4% year-over-year increase to reach EGP 92.3m in Q1 2018. Meanwhile, the net profit registered at EGP 28m in Q1 2018, …
Company working in full swing to develop its distribution network
Companies signed two contracts authorising Ibnsina Pharma to distribute 20+ stock-keeping units of life-saving diabetes care, among other products Ibnsina Pharma, Egypt’s fastest-growing and second-largest pharmaceutical distributor, has signed two contracts with Novo Nordisk, leading manufacturer of insulin and haemophilia treatment, to distribute over 20 stock-keeping units of its diabetes care, haemophilia, and growth disorder …
Company accounted for 24% of Tuesday’s turnover, stock up 3.54%
The IPO has been oversubscribed 17.1 times through more than 500 institutions and individuals
Beltone Financial will take over the initial public offerings of the company’s shares